CMRX: Chimerix Inc Projected Price to Earnings

Chimerix, Inc. (CMRX) specializes in biodefense and oncology, relying on government contracts and future approvals. The company's expected price-to-earnings multiple shows a reversal driven by strict FDA oversight and R&D expenses, yet supported by imipridone patents. The value of 0.00 reflects the latest metric reading, making it possible to distinguish market noise from systemic business degradation on this chart.

Projected Price to Earnings Ratio: Chimerix (CMRX) for 07/04/2022 - 04/26/2025

Metric breakdowns and analytics for Chimerix Inc (CMRX)

- stock value and consensus price forecast:

Price Chart Chimerix|CMRX - Price Target Chart

- market capitalization information:

Market Valuation Chimerix Inc.|CMRX - Value Adjusted for Debt and Cash

- issuer book value statistics:

Net Assets per Single Share Chimerix|CMRX - Total Stockholders' Equity|Market Value to Book Value Ratio chimerix.com|CMRX - Total Business Assets

- debt burden and liquidity indicators:

- company profitability and valuation multiples indicators:

CMRX - Annual Net Income|Future Profit Chimerix, Inc.|CMRX - Market Cap to Earnings|Projected Price to Earnings Chimerix, Inc|CMRX - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Chimerix Inc.|CMRX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Chimerix|CMRX - Earnings per share for the trailing year|Quarterly EPS earnings growth chimerix.com|CMRX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Chimerix, Inc.

Analysis of all company metrics:CMRX Chimerix

Forward P/E is calculated as the ratio of the current market share price to the projected earnings per share, measuring the asset's degree of overvaluation relative to expected earnings. The consensus P/E forecast dynamics for Chimerix, Inc. (CMRX) allow for timely capital adjustments, accounting for the volatility of TEMBEXA orders and ONC201 clinical trial results, to avoid entering a position at a speculative peak.

Competing companies